UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
INSIGHTS & ANALYSIS

Industry Intelligence

Evidence-based coverage of pharmaceutical development, regulatory affairs, and biotech innovation

Clinical Trials10 June 2026· 14 min read

UK Clinical Trial Reforms 2026: Accelerating Approvals

The UK clinical trial regulation package, taking effect on 28 April 2026, is designed to deliver faster, more predictable approvals while preserving participant protections. Its headline operational c

By Tom Okafor, Clinical Trials Correspondent

Research7 May 2026· 13 min read

Microgravity helps find new antimicrobials for superbugs

Microgravity is increasingly recognised as a valuable tool for antimicrobial discovery due to its impact on microbial interactions, competition, and adaptation. Evidence from the International Space S

By Dr. Eleanor Vance, Regulatory Affairs Editor

Cancer4 March 2026· 8 min read

NHS expands abiraterone access for high-risk prostate

NHS England has widened abiraterone acetate access for adults with high-risk non-metastatic prostate cancer, with treatment expected to reach eligible patients within weeks. The change matters because

By Tom Okafor, Clinical Trials Correspondent

Pharmaceutical2 February 2026· 9 min read

Pharmacogenomics Shapes Safer NHS Prescribing in 2026

The NHS has entered a decisive phase in the use of pharmacogenomics, moving from targeted pilots to routine medicines optimisation informed by genetic data. By 2026, evidence from national implementat

By Priya Raghavan, Biotech & Markets Analyst

Research5 January 2026· 10 min read

Personalised medicines: the new frontier, the rise of CRISPR-based therapies in oncology

The first regulatory approvals for a CRISPR-based medicine in the UK and EU marked a turning point for genomic medicine and set expectations for oncology. In 2023, the MHRA licensed exagamglogene auto

By Dr. Eleanor Vance, Regulatory Affairs Editor

Clinical Trials2 January 2026· 12 min read

AI speeds drug discovery as pharma takes risks in 2026

AI drug discovery shifts from promise to operational impact as pharma adopts risk-on posture amid tightening patent cliff timeline in 2026.

By Tom Okafor, Clinical Trials Correspondent

Clinical Trials12 December 2025· 21 min read

UK clinical trials pay surges in 2026

The United Kingdom enters 2026 as one of the most active environments in the world for high-paying clinical trials, particularly early phase studies involving healthy volunteers. Regulatory reforms, f

By Tom Okafor, Clinical Trials Correspondent

Research2 December 2025· 4 min read

The Role of Cathepsin B (CTSB) in Immune Response Studies

Cathepsin B (CTSB) is a lysosomal cysteine protease that plays a key role in protein turnover, antigen processing, and immune regulation. It is widely expressed across mammalian tissues. Recent resear

By Dr. Eleanor Vance, Regulatory Affairs Editor

Research2 December 2025· 13 min read

Stem Cell Therapy for Type 1 Diabetes: Toward a Functional Cure

For over a century, the discovery of insulin transformed Type 1 Diabetes (T1D) from a fatal diagnosis into a survivable condition. Yet, despite remarkable technological advances, patients remain tethe

By Dr. Eleanor Vance, Regulatory Affairs Editor

Research1 December 2025· 4 min read

A Complete Guide to T-Cell Cytotoxicity Assays for Immunology and Immunotherapy Research

The human immune system is a complex network of cells, tissues, and signaling molecules that serves as a defense system. It continuously identifies and eliminates viruses, bacteria, abnormal cells, an

By Dr. Eleanor Vance, Regulatory Affairs Editor

Research26 November 2025· 12 min read

Beyond the pill: how digital therapeutics are transforming chronic care in the NHS

Chronic illness drives demand across the NHS and shapes budgets, workforce planning and service design. People living with multiple long-term conditions account for around half of hospital admissions,

By Dr. Eleanor Vance, Regulatory Affairs Editor

Pharmaceutical24 November 2025· 12 min read

Are bacteriophage therapies the answer to antibiotic resistance

Antimicrobial resistance is accelerating across health systems and undermining routine care. Surgical prophylaxis, oncology regimens and neonatal medicine all depend on reliable antibiotics, yet resis

By Priya Raghavan, Biotech & Markets Analyst

Stay ahead of the curve

Subscribe to our weekly pharmaceutical intelligence digest

Browse

Popular Categories in Pharma Journal

OncologyBiotechnologyPharmaceutical CompaniesClinical ResearchRegulatory, Quality & ComplianceMedical Devices, Diagnostics & EquipmentImmunology & Inflammation
Neuroscience & CNSInfectious Disease & VaccinesRare DiseasesAnimal & Veterinary HealthIndustry Media & AssociationsCell & Gene TherapyDermatology & Aesthetics
Genomics & Precision MedicineRespiratoryCardiovascular & MetabolicContract ManufacturingConsulting, Advisory & MedCommsHaematologyOphthalmology
Private Medical Clinics (London)Recruitment & TalentDigital Health & AIFertility & IVFLab, Reagents & Research ToolsMedical & Health InsuranceWomen's Health

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy